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Targeted next-generation sequencingTenofovir (TFV) is used in combination with other antiretroviral drugs for human immunodeﬁciency virus (HIV)
treatment and prevention. TFV requires two phosphorylation steps to become pharmacologically active; howev-
er, the kinases that activate TFV in cells and tissues susceptible to HIV infection have yet to be identiﬁed. Periph-
eral blood mononuclear cells (PBMC), vaginal, and colorectal tissues were transfected with siRNA targeting
nucleotide kinases, incubated with TFV, and TFV-monophosphate (TFV-MP) and TFV-diphosphate (TFV-DP)
were measured using mass spectrometry–liquid chromatography. Adenylate kinase 2 (AK2) performed the
ﬁrst TFV phosphorylation step in PBMC, vaginal, and colorectal tissues. Interestingly, both pyruvate kinase iso-
zymes, muscle (PKM) or liver and red blood cell (PKLR), were able to phosphorylate TFV-MP to TFV-DP in
PBMC and vaginal tissue, while creatine kinase, muscle (CKM) catalyzed this conversion in colorectal tissue. In
addition, next-generation sequencing of the Microbicide Trials Network MTN-001 clinical samples detected 71
previously unreported genetic variants in the genes encoding these kinases. In conclusion, our results demon-
strate that TFV is activated in a compartment-speciﬁc manner. Further, genetic variants have been identiﬁed
that could negatively impact TFV activation, thereby compromising TFV efﬁcacy inHIV treatment andprevention.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Within the last decade, tenofovir (TFV), prescribed as tenofovir
disoproxil fumarate in its prodrug formulation, has emerged as a critical
component of antiretroviral combination therapy for the treatment of
human immunodeﬁciency virus (HIV) (Schooley et al., 2002; Robbins
et al., 1998).More recently, oral aswell as vaginal and rectalmicrobicide
gel preparations of TFV have been investigated for use in pre-exposure
prophylaxis (PrEP) as an HIV prevention strategy for individuals at
high-risk of viral exposure (Baeten et al., 2012; Mayer et al., 2006;
Anton et al., 2012). TFV is a desirable drug candidate for PrEP due to
the long half-life of active drug TFV-diphosphate (TFV-DP), reportedrEP, pre-exposure prophylaxis;
ar cells; TFV-MP, tenofovir-
01, Microbicide Trials Network
kinase, muscle; PKLR, pyruvate
cle; NME1, NME/NM23 nucleo-
, single-nucleotide variant.
(Clinical Pharmacology), Johns
olfe Street, Biophysics 307,
laine.e@gmail.com (E.E. To),
(N.N. Bumpus).
. This is an open access article underto be 53 h in vaginal tissue homogenate and up to 139 h in vaginal
CD4+ cells following an oral dosing of HIV-uninfected women
(Derdelinckx et al., 2006; Louissaint et al., 2013). That being said,
there has been discrepancy in the prophylactic effect observed for
TFV-based regimens. For example, the Partners in Prevention study
demonstrated a 67–75% reduction in HIV acquisition in serodiscordant
heterosexual couples, iPrEx demonstrated a 44% reduction in men or
transgender women who have sex with men, whereas FEM-PrEP and
VOICE trials showed no signiﬁcant reduction in the rate of infection in
heterosexual women (Grant et al., 2010; Van Damme et al., 2012;
Marrazzo et al., 2015). This disparity has been primarily due to poor ad-
herence. Adjusting for adherence, the differences among these clinical
trials have been attributed to the increased accumulation of active
drug in colorectal versus vaginal tissue. As such, these ﬁndings suggest
that the enzymes responsible for TFV activation may differ between co-
lorectal and vaginal tissue, however, this has not been tested thus far.
Further, while yet to be explored, it can be envisioned that genetic var-
iation in the nucleotide kinases that activate TFV could underlie ob-
served inter-individual differences in tissue TFV-DP concentrations
that has been noted even when adherence is high (Louissaint et al.,
2013; Hendrix et al., 2013; Patterson et al., 2011).
As TFV requires phosphorylation by nucleotide kinases in order to
become pharmacologically active, both local mucosal tissue cellthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1146 J.M. Lade et al. / EBioMedicine 2 (2015) 1145–1152phosphorylation and distant peripheral blood CD4+ cell phosphoryla-
tion with secondary migration to mucosal tissue may be critical in
achieving effective TFV-DP concentrations. If mucosal tissue phosphor-
ylation is an essential contribution to mucosal tissue cell TFV-DP con-
centrations, then the kinases responsible for TFV transformation are
expressed in cells and tissues associated with HIV infection (Robbins
et al., 1998; Kearney et al., 2004). To date, the expression proﬁles of nu-
cleotide kinases in peripheral blood mononuclear cells (PBMC), vaginal
tissue, and colorectal tissue have not been characterized and data dem-
onstrating kinase activity towards TFV and TFV-MP are lacking. In vitro
studies using human T-lymphoid cells demonstrated the mitochondrial
and cytosolic enzyme adenylate kinase isoform 2 (AK2) could catalyze
the phosphorylation of TFV to form TFV-monophosphate (TFV-MP)
(Nobumoto et al., 1998; Robbins et al., 1995; Topalis et al., 2008). Exper-
imental evidence is deﬁcient, however, with regard to the nucleotide
kinase(s) capable of transforming TFV-MP to TFV-DP. TFV-MP has
been reported as a substrate of NME/NM23 nucleoside diphosphate
kinase 1 (NME1) as this enzyme demonstrates broad activity towards
purine nucleoside diphosphates (Robbins et al., 1998; Bourdais et al.,
1996). Yet, in separate studies, NME1 exhibited low to non-detectable
rates of catalysis, while creatine kinase, muscle (CKM) efﬁciently phos-
phorylated TFV-MP andminor catalytic efﬁciency towards TFV-MP was
demonstrated by rabbit pyruvate kinase, muscle (PKM) (Koch et al.,
2009; Varga et al., 2013). Nevertheless, although these kinases exhibit
activity towards TFV or TFV-MP using in vitro model systems, whether
or not they are expressed in cells and tissues susceptible to HIV infection
is unknown.
In the present study, we characterized nucleotide kinase expression
in PBMC, vaginal tissue, and colorectal tissue in order to identify those
that catalyze the phosphorylation of TFV to TFV-MP and TFV-MP to
TFV-DP. Towards this end, we knocked down the protein expression
of AK2, CKM, PKM, pyruvate kinase, liver and red blood cell (PKLR),
and guanylate kinase 1 (GUK1) using siRNA. Neither PKLR nor GUK1
have been previously reported to activate TFV; however, PKLR exhibits
an approximate 70% amino acid sequence identity to the isozyme
PKM and GUK1 has been demonstrated to phosphorylate the antiviral
drug adefovir which is structurally similar to TFV (Gentry et al., 2011).
Taking these studies a step further, we wanted to leverage our identiﬁ-
cation of the nucleotide kinases that activate TFV and test for the exis-
tence of genetic variants in AK2, CKM, PKM, and PKLR. To do so, we
performednext-generation targeted sequencing of genomicDNA isolat-
ed from the plasma of 142 HIV-uninfected female participants of the
Microbicide Trials Network study MTN-001 (Hendrix et al., 2013). In
this work, we have demonstrated at an enzymatic level that TFV is
activated in a tissue-speciﬁc manner. We also put forth an innovative
concept that variation in the genes that encode the nucleotide kinases
that activate TFV may contribute to inter-individual differences
observed clinically. Taken together, these ﬁndings represent a shift in
thinking about the factors that govern variability in TFV efﬁcacy and
pharmacokinetics.
2. Materials and Methods
2.1. siRNA Knockdown of Nucleotide Kinases
PBMC were obtained from Bioreclamation (Westbury, NY), and
fresh vaginal and colorectal biopsies were obtained from the Johns Hop-
kins University School of Medicine Tissue Bank (Baltimore, MD). Donor
information is as follows: PBMC (n=3; 38 y.o. male, 24 y.o. female, and
27 y.o. female); vaginal tissue (n= 3; 31 y.o. female, 48 y.o. female, and
37 y.o. female); colorectal tissue (n = 3; 35 y.o. male, 39 y.o. female,
42 y.o. male). All donors were healthy, HIV-uninfected individuals.
PBMC, vaginal, and colorectal tissues were transfected with siRNA and
incubated with TFV. Homogenized cells and tissues were then
immunoblotted for protein expression and intracellularmetabolites de-
tected using ultra-high performance liquid chromatography–tandemmass spectrometry (uHPLC–MS/MS). Electroporation, immunoblotting,
and uHPLC–MS/MS assay conditions are described in the supplementa-
ry methods.
2.2. Clinical Samples
Plasma was obtained from HIV-uninfected females (n = 142) en-
rolled in the Microbicide Trials Network study MTN-001 across seven
study sites: Umkomaas and Botha's Hill, Durban, South Africa;Makerere
University–Johns Hopkins University Research Collaboration, Kampala,
Uganda; Case Western Reserve University in Cleveland, OH, United
States of America (USA); University of Pittsburgh, Pittsburgh, PA, USA;
University of Alabama at Birmingham, Birmingham, AL, USA; Bronx-
Lebanon Hospital Center, New York City, NY, USA (Hendrix et al.,
2013). The current analysis was approved by the Johns Hopkins
Medicine IRB (NA_00016287).
2.3. Genomic DNA Isolation
Genomic DNAwas isolated from 200 μL of plasma using the GeneJET
Whole Blood Genomic DNA Puriﬁcation Mini Kit (Thermo Fisher
Scientiﬁc,Waltham,MA). PuriﬁedDNAwas eluted using50 μL of elution
buffer.
2.4. Next-generation Sequencing Targeted Enrichment Design
Sequencing was performed using the Illumina TruSeq custom
amplicon v1.5 kit (San Diego, CA). Custom probes targeting the exonic re-
gions of AK2, CKM, PKM, and PKLRwere generated in silico using Illumina
DesignStudio software. The chromosomal coordinates used were as fol-
lows: AK2 1:33473531–1:33502522; CKM 19:45809661–19:45826243;
PKM 15:72492805–15:72523694; and PKLR 1:155259074–1:155271235.
The start and stop coordinates for each target region is detailed in Sup-
plementary Table 1. The ﬁnal design included 102 amplicons listed in
Supplementary Table 2. Sample preparation, sequencing, and data anal-
yses are detailed in the supplementary methods. All genetic variants re-
ported in this study have been submitted to the SNP database under the
submitter handle “BUMPUSLAB.” The phenotypic consequence of mis-
sense variants was assigned using SIFT (sorts intolerant from tolerant
substitutions; J. Craig Venter Institute online tool) and PolyPhen
(polymorphism phenotyping; Harvard University online tool) in silico
prediction tools where amino acid substitutions were scored (Ng and
Henikoff, 2001; Ramensky et al., 2002).
2.5. Statistical Analysis
Statistical analyses were performed using GraphPad Prism (San
Diego, CA). Two-tailed unpaired t testswere performed and signiﬁcance
was denoted as follows: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
2.6. Funding
This work was supported by the NIH grants UM1 AI106707
(Microbicide Trials Network), UM1AI068613 (HIV Prevention Trials
Network), P30 AI094189 (Johns Hopkins University Center for
AIDS Research), R01 GM103853 (awarded to N.N.B.) and by a 2015
PhRMA Foundation Pre Doctoral Fellowship in Pharmacology (awarded
to J.M.L.). The Microbicide Trials Network is funded by NIAID
(UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from
the Eunice Kennedy Shriver NICHD and NIMH, all components of the
NIH.
The funding sponsors had no role in the study design; in the collec-
tion, analysis, and interpretation of data; in the writing of the report;
and in the decision to submit the paper for publication.
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3.1. Nucleotide Kinase Activation of TFV in Cells and Tissues Susceptible to
HIV Infection
In order to identify the nucleotide kinases that activate TFV in PBMC,
vaginal, and colorectal tissue, we delivered siRNA targeted to AK2,
GUK1, PKM, PKLR, and CKM to cells and tissues followed by incubationFig. 1. Targeted siRNA knockdown of nucleotide kinases in PBMC, colorectal tissue, and vagin
colorectal tissue, and vaginal tissue were electroporated with 500 nM non-targeting siRNA or s
or PBMC, respectively. Representative immunoblots demonstrate decreased nucleotide kinase e
siRNA treated (a) PBMC, (b) colorectal tissue, and (c) vaginal tissue were incubated with 10 μM
TFV-MP and TFV-DP were detected using uHPLC–MS/MS as depicted in the corresponding bar
performed using a two-tailed unpaired t test to compare relative levels of anabolite productionwith TFV to test the impact on drug activation. The experiments de-
scribed herein were performed in cells and tissues from healthy, HIV-
uninfected donors that were not administered TFV. Candidate kinases
were screened using immunoblotting in order to test for their expres-
sion in PBMC, vaginal, and colorectal tissues shown in Fig. 1. The non-
targeting, or no target, siRNA lane in the representative immunoblot is
commensuratewith basal expression of each kinase in PBMC, colorectal,
and vaginal tissues, respectively. We found that AK2, which has beenal tissue and the resulting impact on TFV-MP and TFV-DP intracellular formation. PBMC,
iRNA targeting AK2, GUK1, PKM, PKLR, and CKM and incubated for 24 h or 48 h for tissue
xpression with each targeted siRNA treatment relative to the non-targeting siRNA control.
TFV for 12 h (n = 3 per treatment). Intracellular anabolites were extracted from which
graphs showing mean ± standard deviation for each treatment. Statistical analyses were
between non-targeted and targeted siRNA conditions; ** = p ≤ 0.01; *** = p ≤ 0.001.
Table 1
MTN-001 participant demographics and self-identiﬁed ethnicities.
Plasma samples were obtained from 142 HIV-uninfected female participants of the
MTN-001 clinical trial for genomic DNA isolation. Participants were enrolled in study
sites across the United States (USA; n = 72), South Africa (SA; n = 46), and Uganda
(UGA; n = 24).
MTN-001 participant demographics and ethnicities n = 142
Study site Self-identiﬁed ethnicity n (% of n)
USA 72
African American 35 (49)
European American 32 (44)
Asian 2 (3)
Multi-ethnic 2 (3)
Hispanic 1 (1)
SA 46
African 37 (80)
Asian 5 (11)
Multi-ethnic 3 (7)
Bhaca 1 (2)
UGA 24
African 24 (100)
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was expressed ubiquitously in the cells and tissues investigated in this
study. A similar protein expression proﬁle was observed for the nucleo-
tide kinase GUK1. Interestingly, of the candidates examined for the
transformation of TFV-MP to TFV-DP, PKM and PKLR were detectable
in both PBMC and vaginal tissue, while basal expression of either
isoenzyme was not detectable in colorectal tissue using immunoblot
analyses. In contrast, of the kinases tested, CKMwas observed to be ex-
clusively expressed in colorectal tissue and not detectable at the protein
level in PBMC or vaginal tissue. It is important to note that NME1, which
has been reported to transform TFV-MP to TFV-DP with weak catalytic
efﬁciency, was not detectable at the protein level in PBMC, vaginal
tissue, or colorectal tissue (data not shown).
Guided by our preliminary ﬁndings, siRNA was used to knockdown
the following nucleotide kinases AK2, GUK1, PKM, and PKLR in PBMC
(n = 3), AK2, GUK1, and CKM in colorectal tissue (n = 3), and AK2,
GUK1, PKM, and PKLR in vaginal tissue (n = 3). Decreased expression
of each targeted kinase was evaluated relative to the non-targeting
siRNA control using immunoblot analysis (Fig. 1). The intracellular for-
mation of TFV metabolites was detected using uHPLC–MS/MS and the
impact of enzyme loss-of-function on TFV-MP and TFV-DP formation
following incubation with TFV are shown as bar graphs in Fig. 1.
When AK2 was knocked down, TFV-MP decreased to 17 ± 1.4%
(17 / 100 ± 1.4 / 100), 9.5 ± 1.1% (9.5 / 100 ± 1.1 / 100), and 12 ±
1.5% (12 / 100 ± 1.5 / 100; p-value = 3.4E− 6, 3.6E− 5, and 7.2E−
5) of the non-targeting siRNA control in PBMC, colorectal tissue, and
vaginal tissue, respectively. Knockdown of AK2 protein expression also
resulted in a decrease of TFV-DP to 13 ± 1.7% (13 / 100 ± 1.7/100),
15 ± 2.3% (15 / 100 ± 2.3 / 100), and 9 ± 2.2% (9 / 100 ± 2.2 / 100;
p-value = 3.9E− 6, 4.5E− 6, and 2.7E− 5) of non-targeting control
in PBMC, colorectal tissue, and vaginal tissue, respectively. Knockdown
of PKM decreased TFV-DP to 33 ± 5.8% (33 / 100 ± 5.8 / 100) and
27 ± 4.3% (27 / 100 ± 4.3 / 100; p-value = 2.7E− 5 and 8.2E− 5) of
control in PBMC and vaginal tissue, respectively. Additionally, knock-
down of PKLR decreased TFV-DP to 78 ± 6.6% (78 / 100 ± 6.6 / 100)
and 81±7.4% (81 / 100±7.4 / 100; p-value=0.008 and 0.017) of con-
trol in PBMC and vaginal tissue, respectively. When CKM was knocked
down in colorectal tissue, TFV-DP was decreased to 8 ± 2.9%
(8 / 100 ± 2.9 / 100; p-value = 2.2E − 5) of control. The observed
tissue-speciﬁc activation of TFV has been summarized in Fig. 2.
3.2. MTN-001 Participant Demographics and Ethnicities
For this retrospective study, we obtained plasma from 142 of
the total 144 participants of the Microbicide Trials Network study
MTN-001, and their demographics and self-identiﬁed ethnicities are
summarized in Table 1. An approximate half of these participants
were enrolled at the United States study sites (USA; n = 72) and theFig. 2. Schematic summarizing the intracellular activation of the antiretroviral drug TFV in
cells and tissues susceptible to HIV infection. AK2 can transform TFV to TFV-MP in PBMC,
colorectal, and vaginal tissues. PKM and PKLR can transform TFV-MP to the active
anabolite TFV-DP in PBMC and vaginal tissue, while CKM can transform TFV-MP to TFV-
DP in colorectal tissue.remaining participants were enrolled at either the South Africa (SA;
n = 46) or Uganda (UGA; n = 24) study sites.
3.3. Next-generation Sequencing of MTN-001 Clinical Samples
In order to test for the existence of genetic variants within the
nucleotide kinases that activate TFV, we designed a targeted assay to
sequence the exonic regions of AK2, CKM, PKM, and PKLR. GUK1 was
not sequenced in the experiments described herein aswe demonstrated
siRNA knockdown of this enzyme had no signiﬁcant impact on the for-
mation of TFV-MP for PBMC, vaginal, or colorectal tissues. Of the 142
MTN-001 participants sequenced in this study, we observed 57 subjects
(40%, 57/142) to carry single-base variations or deletions in their DNA
that may result in a mutation at the amino acid level. Though this
assay was targeted to exonic regions, we detected genetic variation
within ﬂanking intronic regions as well. The distribution of the variants
and deletions detected for each kinase are depicted using a Venn dia-
gram in Fig. 3. In 40 participants, we observed genetic variants within
only one nucleotide kinase, while 17 individuals carried variants within
two (n = 16) or three (n = 1) nucleotide kinases.
3.4. Targeted Sequencing of AK2
A total of 12 previously unreported single nucleotide variants
(SNVs) and deletions that may impact the protein-coding potential of
the AK2mRNA transcript were detected in 11 participants, six enrolled
in USA study sites, two in SA, and three in UGA. The observed SNVs and
deletions for AK2 DNA reference sequence NM_001625.3 are listed in
Supplementary Table 3. Of the detected AK2 variants, seven missense
variants, which cause amutation at the amino acid level for the encoded
protein, were detected in seven heterozygous individuals at a frequency
of one individual per variant (Table 2). Using in silico tools, three of the
observed missense variants were predicted to have a deleterious and
damaging impact on protein function with a frequency of 2% (3/142
individuals).
3.5. Targeted Sequencing of CKM
A total of 18 previously unreported SNVs and deletions that may
impact the protein-coding potential of the CKMmRNA transcript were
detected in 17 participants, eight enrolled in USA study sites, four in
SA, and ﬁve in UGA. The observed variants for CKM DNA reference
sequence NM_001824.4 are listed in Supplementary Table 4. Of the
detected SNVs, 15 heterozygous participants were found to carry 15
Table 2
AK2missense variants detected in MTN-001 participants.
A total of seven previously unreported AK2missense variants were detected in seven heterozyg
tional consequence of resulting amino acidmutationswere predicted using SIFT and PolyPhen i
N0.05 a tolerated substitution. A PolyPhen score N0.908was suggestive of a probably damaging
and probably damaging AK2missense variants was observed at a frequency of 2% (3/142 indiv
Study
site
Ethnicity AK2 variant
(ref. N alt.)
cDNA
position
Coding DNA sequence
position
P
p
USA African American A N G 249 166 5
USA European American T N C 451 368 1
SA African A N G 511 428 1
SA African G N A 516 433 1
USA African American A N G 583 500 1
UGA African T N A 622 539 1
UGA African G N T 743 660 2
Fig. 3. Distribution of nucleotide kinase genetic variants detected in 57 MTN-001 partici-
pants. Each colored oval is representative of a nucleotide kinase AK2 (blue), CKM (red),
PKM (green), and PKLR (yellow). Non-overlapping regions demonstrate the number of
participants observed to carry single nucleotide variants (SNVs) and deletions within
only one gene (n = 40; AK2 n = 6, CKM n = 8, PKM n = 14, PKLR n = 12). Overlapping
regions demonstrate the number of participants that were observed to carry SNVs and de-
letions in more than one gene (n= 17). For example, moving down the left-hand side of
the diagram, six participants carried AK2 genetic variants alone, two participants carried
variants for AK2 and PKM, one participant carried variants for AK2, PKM, and PKLR, and
one participant carried variants for AK2 and PKLR.
Table 3
CKMmissense variants detected in MTN-001 participants.
A total of 15 previously unreported CKMmissense variants were detected in 15 heterozygousM
consequence of resulting amino acidmutationswere predicted using SIFT and PolyPhen in silico
tolerated substitution. A PolyPhen score N0.908 was suggestive of a probably damaging, 0.447
probably damaging CKMmissense variants was observed at a frequency of 3% (4/142 individu
Study
site
Ethnicity CKM variant
(ref. N alt.)
cDNA
position
Coding DNA sequence
position
P
p
USA European American A N G 419 244
USA African American T N C 435 260
SA African C N T 462 287
UGA African G N A 464 289
UGA African C N T 564 389 1
USA European American C N T 674 499 1
SA African A N G 680 505 1
USA African American A N G 692 517 1
USA Hispanic C N T 758 583 1
UGA African G N C 779 604 2
UGA African T N A 969 794 2
USA African American T N C 981 806 2
SA African A N T 1080 905 3
USA African American A N G 1125 950 3
USA European American T N C 1280 1105 3
1149J.M. Lade et al. / EBioMedicine 2 (2015) 1145–1152CKMmissense variants with a frequency of one individual per variant
(Table 3). Using in silico tools, four of the observed missense variants
were predicted to have a deleterious and damaging impact on protein
functionwith a frequency of 3% (4/142 individuals). Further, the follow-
ing reference single nucleotide polymorphism (SNP) missense variants
rs11559024 (NM_001824.4:c.248TNC) and rs17357122 (NM_001824.
4:c.497GNA) were detected in two heterozygous USA participants
(one individual per variant), and rs17875625 (NM_001824.4:
c.728CNA) was detected in one heterozygous SA participant. Of the de-
tected reference SNPs, only rs17875625 was predicted to have a delete-
rious and damaging impact on protein function.3.6. Targeted Sequencing of PKM
A total of 19 previously unreported SNVs and deletions that may
impact the protein-coding potential of the PKMmRNA transcript were
detected in 19 participants, nine enrolled in USA study sites, ﬁve in SA,
and ﬁve in UGA. The detected variants and deletions for PKMDNA refer-
ence sequenceNM_001206796.1 are listed in Supplementary Table 5. Of
the detected SNVs, 14 PKMmissense variants were detected in 14 het-
erozygous participants at a frequency of one individual per variant
(Table 4). In silico tools were unable to predict the functional impact
of the observed missense variants due to the lack of sequence diversity
required for theperformedmultiple sequence alignments. In addition to
the observed PKM SNVs, three heterozygous USA participants (one indi-
vidual per variant) were found to carry the following reference SNPs:ousMTN-001 participants for the coding DNA reference sequence NM_001625.3. The func-
n silico tools. A SIFT score b0.05 was suggestive of a damaging amino acid substitution and
, 0.447–0.908 a possibly damaging, or b0.447 a benign amino acid substitution. Deleterious
iduals).
rotein
osition
Amino acid
(ref. N alt.)
Exon SIFT prediction PolyPhen prediction
6 S N P 2/6 Deleterious (0.02) Probably damaging (0.95)
23 D N G 4/6 Deleterious (0) Possibly damaging (0.452)
43 L N P 5/6 Deleterious (0) Probably damaging (1)
45 H N Y 5/6 Deleterious (0) Probably damaging (1)
67 I N T 6/6 Deleterious (0.03) Possibly damaging (0.632)
80 E N V 6/6 Tolerated (0.27) Benign (0.009)
20 F N L 6/6 Tolerated (0.08) Benign (0.079)
TN-001 participants for the coding DNA reference sequence NM_001824.4. The functional
tools. A SIFT score b0.05was suggestive of a damaging amino acid substitution and N0.05 a
–0.908 a possibly damaging, or b0.447 a benign amino acid substitution. Deleterious and
als).
rotein
osition
Amino acid
(ref. N alt.)
Exon SIFT prediction PolyPhen prediction
82 Y N H 3/8 Deleterious (0.02) Possibly damaging (0.474)
87 E N G 3/8 Deleterious (0.04) Possibly damaging (0.467)
96 R N H 3/8 Tolerated (0.07) Probably damaging (0.976)
97 H N Y 3/8 Deleterious (0) Probably damaging (0.985)
30 R N H 4/8 Deleterious (0) Probably damaging (0.966)
67 G N S 5/8 Deleterious (0.01) Benign (0.307)
69 F N L 5/8 Tolerated (1) Benign (0.003)
73 Y N H 5/8 Deleterious (0) Possibly Damaging (0.725)
95 D N N 5/8 Tolerated (0.06) Benign (0.099)
02 L N V 5/8 Deleterious (0.03) Possibly damaging (0.878)
65 K NM 7/8 Deleterious (0) Possibly damaging (0.799)
69 H N R 7/8 Tolerated (0.27) Benign (0.002)
02 L N Q 7/8 Deleterious (0) Probably damaging (0.919)
17 L N P 7/8 Deleterious (0) Probably damaging (0.999)
69 K N E 8/8 Tolerated (0.1) Benign (0.001)
Table 4
PKMmissense variants detected in MTN-001 participants.
A total of 14 previously unreported PKMmissense variants were detected in 14 heterozygous MTN-001 participants for the coding DNA reference sequence NM_001206796.1. SIFT and
PolyPhen in silico tools could not predict the functional impact of the observedmissense variants with a high degree of conﬁdence due to the lack of sequence diversity that is required for
the performed multiple sequence alignments.
Study site Ethnicity PKM variant
(ref. N alt.)
cDNA position Coding DNA
sequence position
Protein position Amino acid
(ref. N alt.)
Exon
USA African American C N T 643 244 82 A N T 3/12
USA Asian G N C 753 354 118 N N K 3/12
SA African T N A 754 355 119 T N S 3/12
USA European American A N T 919 520 174 S N T 5/12
SA African A N T 1052 653 218 L N Q 6/12
UGA African T N C 1103 704 235 Y N C 6/12
UGA African C N A 1483 1084 362 D N Y 8/12
USA Multiracial T N C 1489 1090 364 I N V 8/12
UGA African C N T 1600 1201 401 A N T 8/12
UGA African T N C 1628 1229 410 K N R 9/12
USA African American T N G 1642 1243 415 T N P 9/12
SA Asian C N T 1820 1421 474 R N Q 10/12
UGA African C N T 1897 1498 500 A N T 10/12
USA European American T N C 2114 1715 572 K N R 12/12
1150 J.M. Lade et al. / EBioMedicine 2 (2015) 1145–1152stop gained variants rs180716407 (NM_001206796.1:c.14GNC) and
rs151078084 (NM_001206796.1:c.1354GNA) and the missense variant
rs147939689 (NM_001206796.1:c.389CNA).
3.7. Targeted Sequencing of PKLR
A total of 22 previously unreported SNVs and deletions that may
impact the protein-coding potential of the PKLRmRNA transcript were
detected in 21 participants, 14 enrolled in USA study sites, four in SA,
and three in UGA. The variants and deletions for PKLR DNA reference
sequence NM_000298.5 are listed in Supplementary Table 6. Of the
observed SNVs, 15 PKLRmissense variants were detected in 15 hetero-
zygous participants at a frequency of one individual per variant
(Table 5). Using in silico tools, four of the detected missense variants
were predicted to have both a deleterious and damaging impact on pro-
tein function with a frequency of 3% (4/142 individuals). The reference
SNP missense variant rs147689373 (NM_000298.5:c.829CNT) was
detected in one heterozygous SA participant.
4. Discussion
This study identiﬁed the nucleotide kinases that activate TFV in cells
and tissues susceptible to HIV infection. Our data suggests that AK2mayTable 5
PKLRmissense variants detected in MTN-001 participants.
A total of 15 previously unreported PKLRmissense variants were observed in 15 heterozygousM
consequence of resulting amino acid substitutions were predicted using SIFT and PolyPhen in
N0.05 a tolerated substitution. A PolyPhen score N0.908was suggestive of a probably damaging
and probably damaging PKLRmissense variants was observed at a frequency of 3% (4/142 indi
Study site Ethnicity PKLR variant
(ref. N alt.)
cDNA
position
Coding DNA
sequence position
P
p
SA African C N T 128 89
SA African A N T 206 167
USA African American T N A 251 212
USA African American A N T 277 238
UGA African A N G 287 248
USA African American A N T 337 298 1
USA European American C N T 386 347 1
USA Hispanic G N A 674 635 2
USA African American T N C 730 691 2
USA African American C N T 814 775 2
UGA African T N C 908 869 2
USA European American G N T 990 951 3
USA African American C N T 1066 1027 3
USA European American T N C 1346 1307 4
SA African C N T 1357 1318 4be a key contributor to systemic and localized TFV activation as siRNA
knockdown in PBMC, vaginal tissue, and colorectal tissue resulted in sig-
niﬁcantly decreased formation of TFV metabolites. Additionally, we
demonstrated that PKLR can contribute to TFV-DP formation in PBMC
and vaginal tissue. PKLR is highly expressed in the liver and therefore
may be critical for the activation of oral TFV preparations that undergo
ﬁrst-pass metabolism. Interestingly, we observed CKM protein expres-
sion to be limited to colorectal tissue. TFV-DP concentrations in colorec-
tal tissue exceed those in vaginal tissue with an oral dose of TFV and
tissue-speciﬁc expression of CKM could contribute to this phenomenon.
Additionally in this study, we examined a potential role for the nucleo-
tide diphosphate kinase NME1. We did not detect NME1 expression at
the protein level in PBMC, vaginal, or colorectal tissue, suggesting
NME1 is unlikely to contribute to the activation of TFV in the cells and
tissues investigated.
Through our work, we identiﬁed AK2, CKM, PKM, and PKLR as candi-
dates for examination in a retrospective clinical study. In doing so, we
detected 71 previously unreported variants in the genes encoding
these kinases. The coverage threshold implemented in our analyses
was in line with the American College of Medical Genetics and
Genomics clinical laboratory standards for next-generation sequencing,
increasing the conﬁdence in the variants called (Rehm et al., 2013).
These discovered variants, however, were not validated in parallelTN-001 participants for the coding DNA reference sequenceNM_000298.5. The functional
silico tools. A SIFT score b0.05 was suggestive of a damaging amino acid substitution and
, 0.447–0.908 a possibly damaging, or b0.447 a benign amino acid substitution. Deleterious
viduals).
rotein
osition
Amino acid
(ref. N alt.)
Exon SIFT prediction PolyPhen prediction
30 G N E 1/11 Deleterious (0.01) Probably damaging (0.995)
56 F N Y 2/11 Tolerated (0.29) Benign (0.075)
71 E N V 2/11 Deleterious (0) Probably damaging (0.919)
80 S N T 2/11 Tolerated (0.19) Benign (0.087)
83 V N A 2/11 Tolerated (0.97) Benign (0.001)
00 S N T 3/11 Tolerated (0.06) Benign (0.32)
16 R N Q 3/11 Deleterious (0) Probably damaging (0.996)
12 P N L 5/11 Deleterious (0.03) Benign (0.094)
31 I N V 5/11 Tolerated (0.86) Benign (0.002)
59 V NM 6/11 Deleterious (0.03) Possibly damaging (0.892)
90 K N R 6/11 Tolerated (0.24) Possibly damaging (0.879)
17 H N Q 6/11 Tolerated (0.98) Possibly damaging (0.577)
43 E N K 7/11 Deleterious (0) Probably damaging (0.992)
36 Q N R 9/11 Tolerated (0.27) Benign (0.423)
40 E N K 9/11 Deleterious (0.05) Possibly damaging (0.858)
1151J.M. Lade et al. / EBioMedicine 2 (2015) 1145–1152using Sanger sequencing. We detected seven genetic variants in CKM,
PKM, and PKLR that have been reported in the SNP database. The CKM
SNPs rs11559024 and rs17357122 detected in MTN-001 European
American participants have frequencies of 1–3% in Western European
populations as reported by the 1000 Genomes Project (Abecasis et al.,
2012). These populations also exhibit a comparable frequency for the
PKM SNP rs180716407 detected in one European American participant,
and African sub-populations of Nigeria, Kenya, and Sierra Leone have a
frequency of 1–2% for the PKLR SNP rs147689373 detected in one
South African participant. Population genetics aside, the impact of
these discovered and reported genetic variants on enzymatic activity
is unknown. For the detected missense variants, however, we were
able to predict the phenotypic consequence of resulting amino acid
mutations using the in silico bioinformatic tools SIFT and PolyPhen.
For example, one MTN-001 participant carried the CKMmissense vari-
ant NM_001824.4:c.389GNA, causing a deleterious and damaging
amino acid mutation of R130H. In line with this, a study characterizing
TFV-MP binding within the active site of CKM observed this particular
amino acid residue R130 to form strong ionic interactions with its
substrates (Varga et al., 2013). Moreover, one can envision that such a
mutation may interfere with substrate binding and, therefore, decrease
rates of phosphorylation. That being said, the variants predicted in our
study to negatively impact kinase function ultimately need to be tested
in vitro using site-directedmutagenesis in order to elucidate their effect
on activity towards TFV and TFV-MP.
Due to the frequency of the genetic variants detected within the
MTN-001 participants, we were unable to make strong correlations
with our published TFV pharmacokinetic data (Hendrix et al., 2013).
Additionally, adherence is a confounding issue for HIV PrEP studies
making it particularly difﬁcult to execute these analyses in a retrospec-
tive study. As a proof of concept, however, it is worth noting that an
African American participant carrying a predicted dysfunctional
missense variant for PKLR exhibited a three-fold greater ratio of TFV to
TFV-DP in vaginal tissue compared to homozygous wild-type partici-
pants with daily use of a 1% TFV microbicide gel and is commensurate
with lower TFV-DP tissue concentrations. In order to perform a power-
ful analysis, a pharmacokinetic study design is required in which
healthy volunteers would be enrolled based on genotype in the same
manner used for our recent study of the anti-HIV drug maraviroc (Lu
et al., 2014). Further, as this preliminary pharmacogenomics study
was limited to females it would also be of interest to perform a similar
analysis in men in order to investigate potential sexual dimorphisms
in allele frequencies.
In conclusion, our results present a fundamental shift when con-
sidering the factors that govern TFV disposition as differing routes of
activation could contribute to tissue-speciﬁc pharmacokinetic–
pharmacodynamic relationships. Further, in identifying the nucleotide
kinases responsible for TFV activation in PBMC, vaginal tissue, and colo-
rectal tissue, we were able to perform targeted sequencing of the genes
encoding these kinases using clinical samples of the MTN-001 Microbi-
cide Trials Network study.We detected genetic variants in these kinases
predicted to have deleterious and damaging phenotypes, demonstrat-
ing that there could be a genetic basis for inter-individual variation in
TFV drug levels. Taken together, the results from this study are pushing
an important concept forward in that HIV PrEP is not a one-size-ﬁts-all
preventative approach, and these data can guide future clinical studies
to investigate the impact of nucleotide kinase genetic variants on TFV
pharmacokinetics.
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